Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 15/20 | 0.81 |
| ▸ | MMP1 | P03956 | 9/20 | 0.81 |
| ▸ | MMP12 | P39900 | 1/20 | 0.81 |
| ▸ | MMP13 | P45452 | 1/20 | 0.81 |
| ▸ | MMP9 | P14780 | 6/20 | 0.63 |
| ▸ | MMP3 | P08254 | 6/20 | 0.63 |
| ▸ | MMP8 | P22894 | 5/20 | 0.63 |
| ▸ | MMP7 | P09237 | 2/20 | 0.63 |
| ▸ | FCER2 | P06734 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27547968 | 1.00 | MMP2 (0.81) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL4634587 | 0.90 | MMP2 (1.00) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL4634581 | 0.90 | MMP2 (1.00) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL4634577 | 0.90 | MMP2 (1.00) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL29838142 | 0.90 | MMP2 (1.00) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL5099222 | 0.88 | MMP2 (0.80) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL10136032 | 0.88 | MMP2 (0.73) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL4634106 | 0.86 | MMP1 (0.70) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL27573505 | 0.86 | MMP1 (0.70) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL4634107 | 0.86 | MMP1 (0.70) | MMP2MMP1MMP12MMP13MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931624-A1 | USE OF AN AUREOLYSIN INHIBITOR FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS CHARACTERISED BY COLONISATION WITH STAPHYLOCOCCUS AUREUS | Serentis Limited (GB) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007025999-A1 | USE OF AN AUREOLYSIN INHIBITOR FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS CHARACTERISED BY COLONISATION WITH STAPHYLOCOCCUS AUREUS | SERENTIS LIMITED (GB) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | SERENTIS LIMITED (GB) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | MMP8, CUTA, MMP1 | MMP2 12/4885MMP1 3/4885MMP12 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.